After Paxlovid, the Pharma Pfizer Small Molecular Oral Drug was not included in China Medical Insurance, Chinese medical experts revealed that domestic small molecular drugs are undergoing clinical trials.Essence
According to the China News Agency, Wang Guiqiang, director of the Department of Infectious Diseases of the First Hospital of Peking University, revealed on Wednesday (January 11) that Chinese domestic small molecular drugs are undergoing clinical trials and said that it is believed that with research and development,More and more related drugs will go public to meet clinical needs.
Wang Guiqiang pointed out that antiviral therapy is an important part of comprehensive therapy. The biggest advantage of small molecular drug orally is that it is convenient to use in the community home clinic. At present, the demand is indeed very large.
He reminded that small molecules oral antiviral drugs are generally best used within five days after infection, and the effect of use after five days is not good.At the same time, people with intensive high -risk people, namely the elderly, the basic disease, and no vaccine are preferred, which can reduce the risk of intensive illness. The value of the general population is not great after infection.
In the tenth edition of the crown disease diagnosis and treatment plan announced in China, antiviral therapy includes Paxlovid (China known as "Namedovir Picine/Litnaville"), Azf fixed tablets, Mo Mo, Mo Mo, Mo Mo, MoThe Molnupiravir, monoclonal antibodies, still injection crown patient immunoglobulin, and recovery of plasma.
On the other hand, Liu Yong, president of China National Pharmaceutical Group, revealed in an interview with the media on Wednesday that Monabeville, the crown disease of Merida Corporation, represented by the Chinese Medicine GroupFriday (January 13) can be launched in China.According to previous reports, the number of Moniliibavir drugs was hundreds of thousands of boxes.
